Home » Topics » Ear, nose and throat, BioWorld Science

Ear, nose and throat, BioWorld Science
RSS

Spiral Therapeutics initiates phase I trial of new hearing loss drug, LPT-99

Dec. 19, 2018

Seliforant shown not to affect vigilance, cognitive performance during motion stimulus

Dec. 14, 2018

Novus initiates phase I trial of OP-0201 for otitis media

Nov. 29, 2018

Sensorion signs letter of intent with Institut Pasteur for hearing loss gene therapy programs

Nov. 23, 2018

Novartis discloses protein atonal homolog 1 activators

Oct. 18, 2018

Insm1 keeps hair cells in 'n' out

Oct. 17, 2018

European clearance for phase II study of SENS-401 for sudden sensorineuronal hearing loss

Aug. 20, 2018

Discovery of a novel enzymatic function of histone deacetylase 11

Aug. 14, 2018

First patients dosed in phase I/II study of FX-322

Aug. 8, 2018

Otonomy initiates additional phase III trial of Otividex for Meniere's disease

July 27, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...